Nivolumab and ipilimumab

An open-label, randomized, phase III study (CheckMate743 [NCT02899299]) included 605 patients with advanced treatment-naive pleural mesothelioma. Patients were randomly assigned to receive either nivolumab and ipilimumab (n = 303) or chemotherapy (n = 302).[1]

An open-label, randomized, phase III study (CheckMate743 [NCT02899299]) included 605 patients with advanced treatment-naive pleural mesothelioma. Patients were randomly assigned to receive either nivolumab and ipilimumab (n = 303) or chemotherapy (n = 302).[1]

At the prespecified interim analysis, patients who received nivolumab plus ipilimumab had significantly extended overall survival (OS) compared with patients who received chemotherapy (median OS, 18.1 months [95% confidence interval (CI), 16.8–21.4] vs. 14.1 months [12.4–16.2]; hazard ratio [HR], 0.74; 96.6% CI, 0.60–0.91; P = .002).[1][Level of evidence A1]

An open-label, randomized, phase III study (CheckMate743 [NCT02899299]) included 605 patients with advanced treatment-naive pleural mesothelioma. Patients were randomly assigned to receive either nivolumab and ipilimumab (n = 303) or chemotherapy (n = 302).[1]

The median progression-free survival (PFS) and objective response rates were not significantly different.

An open-label, randomized, phase III study (CheckMate743 [NCT02899299]) included 605 patients with advanced treatment-naive pleural mesothelioma. Patients were randomly assigned to receive either nivolumab and ipilimumab (n = 303) or chemotherapy (n = 302).[1]

Grade 3 to 4 treatment-related adverse events occurred in 91 of 300 patients (30%) who received nivolumab plus ipilimumab and 91 of 284 patients (32%) who received chemotherapy.

An open-label, randomized, phase III study (CheckMate743 [NCT02899299]) included 605 patients with advanced treatment-naive pleural mesothelioma. Patients were randomly assigned to receive either nivolumab and ipilimumab (n = 303) or chemotherapy (n = 302).[1]

Three (1%) treatment-related deaths occurred among patients who received nivolumab plus ipilimumab (pneumonitis, encephalitis, and heart failure) and one (<1%) among patients who received chemotherapy (myelosuppression).